Avastin
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you your search results in order of date.
3274 records returned
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the approval of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM), the most aggressive type of primary malignant brain cancer. (Source: Roche Media News)
Source: Roche Media News - November 20, 2009 Category: Pharmaceuticals Source Type: organizations
Patients Win With Immediate Avastin Payment ReversalEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Following efforts by the American Academy of Ophthalmology with the help of the American Society of Retina Specialists, the Macula Society, the Retina Society and Congressional allies, the Center for Medicare and Medicaid Services (CMS) said that it will retract an Oct. 1 payment policy for small doses of Avastin. Avastin, a cancer drug, is used in smaller doses to treat eye diseases such as age-related macular degeneration (AMD). (Source: Eye Health / Optometry News From Medical News Today)
Source: Eye Health / Optometry News From Medical News Today - November 20, 2009 Category: Opthalmology Tags: Eye Health / Blindness Source Type: news
Patients Win With Immediate Avastin Payment ReversalEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Following efforts by the American Academy of Ophthalmology with the help of the American Society of Retina Specialists, the Macula Society, the Retina Society and Congressional allies, the Center for Medicare and Medicaid Services (CMS) said that it will retract an Oct. 1 payment policy for small doses of Avastin. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 20, 2009 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Molecular Targets in Malignant Pleural Mesothelioma Treatment.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Malignant mesothelioma is an aggressive tumour of the serosal surfaces with poor prognosis and increasing incidence due to widespread previous asbestos exposure. Relative chemotherapeutic and radiotherapeutic resistance makes malignant pleural mesothelioma (MPM) difficult to manage, even though encouraging results were achieved with multimodality treatment. Better knowledge of angiogenesis and molecular pathways involved in MPM seems to be the right way to define new targets for systemic treatment. Neoangiogenesis may be considered as a critical step in the development of mesothelioma. Vascular endothelial growth facto...
Source: Current Drug Targets - November 19, 2009 Category: Drugs & Pharmacology Authors: Pasello G, Favaretto A Tags: Curr Drug Targets Source Type: journals
Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer [Gastrointestinal Cancer]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
The maximum-tolerated dose of capecitabine was 1,660 mg/m2. The recommended capecitabine dose in this cytotoxic doublet/biologic doublet regimen is 1,440 mg/m2; this regimen is under evaluation in an ongoing phase II study. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Starling, Watkins, Cunningham, Thomas, Webb, Brown, Thomas, Oates, Chau Tags: Chemotherapy Gastrointestinal Cancer Source Type: journals
World's First Delivery Of Intra-Arterial Avastin Directly Into Brain TumorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 18, 2009 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news
World's First Delivery Of Intra-Arterial Avastin Directly Into Brain TumorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 18, 2009 Category: Cancer & Oncology Tags: Neurology / Neuroscience Source Type: news
Patient Receives World's First Delivery Of Intra-arterial Avastin Directly Into A Malignant Brain TumorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 18, 2009 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Patient Receives World's First Delivery Of Intra-arterial Avastin Directly Into A Malignant Brain TumorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 18, 2009 Category: Cancer & Oncology Tags: Cancer / Oncology Source Type: news
Targeted therapy of metastatic breast cancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract Breast cancer is a heterogeneous disease characterised by a dysregulation of multiple pathways related to cell differentiation,
cell cycle control, apoptosis, angiogenesis and development of metastasis. Acting against these pathways provides therapeutic
targets for new targeted biologic therapies, which, in the future, might constitute a key for fighting cancer. The development
of molecular technology in recent years has allowed a further comprehension of these mutations and dysregulated pathways leading
to oncogenesis. New targeted biologic therapies will block essential functions of cancer cells a...
Source: Clinical and Translational Oncology - November 18, 2009 Category: Cancer & Oncology Tags: Clinical and Translational Oncology Source Type: journals
World's first delivery of intra-arterial Avastin directly into brain tumorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Neurosurgeons have performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously or throughout their body. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 18, 2009 Category: Science Source Type: news
Applications submitted to FDA for bevacizumab (Avastin®) in first-line treatment of metastatic breast cancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: BioSpace
Area: News
According to BioSpace, Genentech has submitted two supplemental Biologics License Applications (sBLAs) to the U.S. FDA for bevacizumab (Avastin®) for the first-line treatment of women with advanced (metastatic) HER2-negative breast cancer.
One sBLA is based on the Phase III AVADO study that compared bevacizumab in combination with docetaxel chemotherapy, to docetaxel alone in this setting. The other is based on the Phase III RIBBON 1 study that investigated bevacizumab in combination with a taxane, anthracycline-based or capecitabine chemotherapy (compared with the chemotherapies al...
Source: NeLM - Oncology - November 18, 2009 Category: Cancer & Oncology Source Type: organizations
OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlled study of ZYBRESTAT (fosbretabulin) in patients with advanced non-small cell lung cancer (NSCLC). The data from this planned interim safety analysis indicated that the combination of fosbretabulin with carboplatin and paclitaxel plus bevacizumab (Avastin(R)) appeared to ...
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news
Genentech Submits Supplemental Applications To FDA For Avastin Combined With Commonly Used Chemotherapies For Women With Advanced Breast CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 17, 2009 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Genentech Submits Supplemental Applications To FDA For Avastin Combined With Commonly Used Chemotherapies For Women With Advanced Breast CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). (Source: Breast Cancer News From Medical News Today)
Source: Breast Cancer News From Medical News Today - November 17, 2009 Category: Cancer & Oncology Tags: Breast Cancer Source Type: news
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Dr... Biopharmaceuticals, OncologyGenentech, Roche Group, Avastin, bevacizumab, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
Applications to allow Avastin to be combined with commonly used chemotherapies in advanced breast cancer submitted to FDAEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the phase III AVADO study that investigated Avastin in combination with docetaxel chemotherapy. The other is based on the phase III RIBBON-1 study that investigated Avastin in combination with a taxane or anthracycline-based chemotherapy or...
Source: Roche Investor Update - November 17, 2009 Category: Pharmaceuticals Source Type: organizations
World's first delivery of intra-arterial Avastin directly into brain tumorEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously or throughout their body. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2009 Category: Global & Universal Source Type: news
Breaching a Barrier to Fight Brain CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
An experimental treatment for glioblastoma suppresses a barrier to deliver a drug directly to brain tumors. (Source: NYT > Health)
Source: NYT > Health - November 16, 2009 Category: Consumer Health News Authors: By DENISE GRADY Tags: Avastin (Drug) Tumors Brain Medicine and Health Chemotherapy Source Type: news
Bevacizumab for recurrent ependymomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions: The radiographic response rate to bevacizumab-containing regimens is high. A prospective study is warranted. (Source: Neurology)
Source: Neurology - November 16, 2009 Category: Neurology Authors: Green, R. M., Cloughesy, T. F., Stupp, R., DeAngelis, L. M., Woyshner, E. A., Ney, D. E., Lassman, A. B. Tags: All Oncology, Primary brain tumor, Spinal cord tumor, Chemotherapy-tumor ARTICLES Source Type: journals
Bevacizumab: Arterial hypertension: 2 case reportsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 16, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals
Bevacizumab: Epistaxis and hypertension: 3 case reportsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals
Bevacizumab/paclitaxel: Fatal intestinal perforation: case reportEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals
Bevacizumab: Foveal vascular zone enlargement after intravitreal injection in a diabetic patient: case reportEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals
Bevacizumab: Intestinal perforation in an elderly patient: case reportEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions In medically fit older patients, bevacizumab provides similar PFS and OS benefits as in younger patients.
Content Type Journal ArticleCategory Original PaperDOI 10.1007/s00432-009-0712-3Authors
James Cassidy, Cancer Research UK Glasgow UKLeonard B. Saltz, Memorial Sloan-Kettering Cancer Center New York NY USABruce J. Giantonio, University of Pennsylvania Philadelphia PA USAFairooz F. Kabbinavar, UCLA School of Medicine Los Angeles CA USAHerbert I. Hurwitz, Duke University Medical Center Durham NC USAUlrich-Peter Rohr, F. Hoffmann-La Roche Basel Switzerland
Journal Journal of Cancer Re...
Source: Journal of Cancer Research and Clinical Oncology - November 10, 2009 Category: Cancer & Oncology Tags: Journal of Cancer Research and Clinical Oncology Source Type: journals
Single intravitreal injection of triamcinolone combined with bevacizumab for the treatment of diffuse diabetic macular oedema refractory to grid photocoagulationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - November 10, 2009 Category: Opthalmology Authors: Marco S. Folgosa, André Messias, Clécio Takata, Rogério A. Costa, Ingrid U. Scott, Rodrigo Jorge Source Type: journals
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions: Bevacizumab plus capecitabine has no activity in patients with very advanced ACC. Hence this regimen can not be recommended as a salvage therapy.
PMID: 19903796 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - November 10, 2009 Category: Endocrinology Authors: Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B, Fassnacht M Tags: Eur J Endocrinol Source Type: journals
A New Macular Dystrophy With Anomalous Vascular Development, Pigment Spots, Cystic Spaces, and Neovascularization [Clinical Sciences]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions This spotted cystic neovascular macular dystrophy appears to represent a new autosomal dominant retinal condition. Because these patients are at risk for choroidal neovascularization, identification of the responsible gene may provide insight into the mechanisms of pathological neovascularization. (Source: Archives of Opthalmology)
Source: Archives of Opthalmology - November 9, 2009 Category: Opthalmology Authors: Mahajan, V. B., Russell, S. R., Stone, E. M. Tags: Ophthalmology, Ophthalmological Disorders, Choroidal Neovascularization, Corneal Disorders, Macular Disorders, Retinal/ Chorioretinal Disorders, Genetics, Genetic Disorders Clinical Sciences Source Type: journals
Anti-Malignancy Agent Avastin Obtained Approval for Additional Indication of Non-Small Cell Lung CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Please find attached a press release issued by Chugai in Japan (Source: Roche Investor Update)
Source: Roche Investor Update - November 9, 2009 Category: Pharmaceuticals Source Type: organizations
Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - November 9, 2009 Category: Opthalmology Authors: Farzin Forooghian, Emily Y. Chew, Catherine B. Meyerle, Catherine Cukras, Wai T. Wong Source Type: journals
Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions: In response to four intravitreal injections of bevacizumab during 6 months, a substantial improvement in visual acuity and reduction in central retinal thickness were achieved. A randomized clinical trial is warranted to further evaluate the efficacy and safety of this treatment modality. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - November 9, 2009 Category: Opthalmology Authors: Peep V. Algvere, Gunvor von Wendt, Johann Gudmundsson, Stefan Seregard, Anders Kvanta Source Type: journals
Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-upEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural
outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab
offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision
at 6 months
Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-009-1211-6Authors
Rita Ehrlich, Indiana University School of Medicine Department of Ophthalmology 702 Rotary Circle Indianapolis IN 4620...
Source: Graefe's Archive for Clinical and Experimental Ophthalmology - November 7, 2009 Category: Opthalmology Tags: Graefe's Archive for Clinical and Experimental Ophthalmology Source Type: journals
FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
On May 5, 2009, the U.S. Food and Drug Administration granted accelerated approval to bevacizumab injection (Avastin(R); Genentech, Inc., South San Francisco, CA) as a single agent for patients with glioblastoma multiforme (GBM) with progressive disease following prior therapy. The approval was based on durable objective responses (independent radiologic review with stable or decreasing corticosteroid use). Two trials evaluating bevacizumab, 10 mg/kg by i.v. infusion every 2 weeks, were submitted. One trial also randomized patients to bevacizumab plus irinotecan treatment. All patients had received prior surgery, radio...
Source: The Oncologist - November 6, 2009 Category: Cancer & Oncology Authors: Cohen MH, Li Shen Y, Keegan P, Pazdur R Tags: Oncologist Source Type: journals
Docetaxel: its role in current and future treatments for advanced gastric cancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract A globally accepted standard chemotherapy remains undetermined in gastric cancer, but the recent introduction of active “new-generation
agents” such as taxanes, irinotecan (CPT-11), oxaliplatin, S-1, and capecitabine, offers hope for markedly improving patient
outcomes. Docetaxel, as well as the other new-generation agents, plays a key role in the development of the new-era chemotherapy,
and the incorporation of taxanes has provided several regimens, such as docetaxel/cisplatin/5-fluorouracil (5-FU) (DCF), that
could become standard treatment. The DCF regimen is now regarded as a standard treatm...
Source: Gastric Cancer - November 4, 2009 Category: Gastroenterology Tags: Gastric Cancer Source Type: journals
Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Content Type Journal ArticleCategory Medical OncologyDOI 10.1245/s10434-009-0798-5Authors
Dimosthenis Ziogas, University of Ioannina Department of Surgery, School of Medicine Ioannina GreeceDimitrios Roukos, University of Ioannina Department of Surgery, School of Medicine Ioannina Greece
Journal Annals of Surgical OncologyOnline ISSN 1534-4681Print ISSN 1068-9265 (Source: Annals of Surgical Oncology)
Source: Annals of Surgical Oncology - November 4, 2009 Category: Cancer & Oncology Tags: Annals of Surgical Oncology Source Type: journals
Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSIONS: The combination of radiotherapy with bevacizumab is feasible and results in a high rate of durable complete responses in patients with LA/I-CRC. Radiosensitization may occur through a direct effect on tumor cells followed by a wide scale suppression of transcription factors and genes involved in DNA repair and proliferation. (Clin Cancer Res 2009;15(22):7069-76).
PMID: 19887481 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 3, 2009 Category: Cancer & Oncology Authors: Koukourakis MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, Sivridis E, Harris AL, Tags: Clin Cancer Res Source Type: journals
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)
Source: Clinical Trials And Noteworthy Treatments For Brain Tumors - November 1, 2009 Category: Cancer & Oncology Source Type: clinical trials
